MX9803563A - Preparacion terapeutica para la administracion transdermica de principios activos. - Google Patents

Preparacion terapeutica para la administracion transdermica de principios activos.

Info

Publication number
MX9803563A
MX9803563A MX9803563A MX9803563A MX9803563A MX 9803563 A MX9803563 A MX 9803563A MX 9803563 A MX9803563 A MX 9803563A MX 9803563 A MX9803563 A MX 9803563A MX 9803563 A MX9803563 A MX 9803563A
Authority
MX
Mexico
Prior art keywords
active substances
transdermal administration
therapeutic preparation
preparation
additives
Prior art date
Application number
MX9803563A
Other languages
English (en)
Inventor
Bodo Asmussen
Andreas Koch
Rudolf Matusch
Original Assignee
Lohmann Therapie Syst Lts
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lohmann Therapie Syst Lts filed Critical Lohmann Therapie Syst Lts
Publication of MX9803563A publication Critical patent/MX9803563A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

El preparado propuesto contiene aditivos, los cuales hacen que los principios activos que son por lo regular solo reabsorbidos en forma inadecuada a través de la piel, sean absorbidos más rápidamente. El preparado se caracteriza en que los aditivos son inhibidores HMG-CoA-reductasa.
MX9803563A 1995-11-06 1998-05-06 Preparacion terapeutica para la administracion transdermica de principios activos. MX9803563A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19541260A DE19541260A1 (de) 1995-11-06 1995-11-06 Therapeutische Zubereitung zur transdermalen Applikation von Wirkstoffen durch die Haut

Publications (1)

Publication Number Publication Date
MX9803563A true MX9803563A (es) 1998-09-30

Family

ID=7776710

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9803563A MX9803563A (es) 1995-11-06 1998-05-06 Preparacion terapeutica para la administracion transdermica de principios activos.

Country Status (21)

Country Link
US (1) US6379696B1 (es)
EP (1) EP0859595B1 (es)
JP (1) JP2001507331A (es)
KR (1) KR100445940B1 (es)
CN (1) CN1201385A (es)
AT (1) ATE186209T1 (es)
AU (1) AU716896B2 (es)
CZ (1) CZ289143B6 (es)
DE (2) DE19541260A1 (es)
ES (1) ES2141534T3 (es)
GR (1) GR3032523T3 (es)
IL (1) IL124279A (es)
MX (1) MX9803563A (es)
MY (1) MY132407A (es)
NO (1) NO982006L (es)
NZ (1) NZ318783A (es)
PL (1) PL326497A1 (es)
PT (1) PT859595E (es)
SK (1) SK281405B6 (es)
WO (1) WO1997017061A1 (es)
ZA (1) ZA969271B (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19830732B4 (de) * 1998-07-09 2008-11-13 Lts Lohmann Therapie-Systeme Ag Zusammensetzung, enthaltend mindestens einen die Blutfettwerte beeinflussenden Wirkstoff und seine Verwendung
CA2422200A1 (en) * 2000-09-08 2002-03-14 Alza Corporation Methods for inhibiting decrease in transdermal drug flux by inhibition of pathway closure
US20020187169A1 (en) * 2001-05-11 2002-12-12 Shoujun Chen Kavalactone compositions
KR20060052931A (ko) * 2003-07-28 2006-05-19 알자 코포레이션 경피용 와파린-포함 전달 시스템
EP1731147A4 (en) * 2004-03-31 2010-06-30 Kowa Co EXTERNAL PREPARATION
SI2018153T1 (sl) 2006-04-26 2012-08-31 Rosemont Pharmaceuticals Ltd Tekoči oralni sestavki
EP2019679B1 (en) 2006-05-23 2018-06-20 Theracos, Inc. Glucose transport inhibitors and methods of use
US8748419B2 (en) 2006-06-16 2014-06-10 Theracos, Inc. Treating obesity with muscarinic receptor M1 antagonists
US7893053B2 (en) 2006-06-16 2011-02-22 Theracos, Inc. Treating psychological conditions using muscarinic receptor M1 antagonists
US7652767B2 (en) * 2006-10-19 2010-01-26 Sporian Microsystems, Inc. Optical sensor with chemically reactive surface
US20080152592A1 (en) * 2006-12-21 2008-06-26 Bayer Healthcare Llc Method of therapeutic drug monitoring
WO2008115224A2 (en) * 2007-03-20 2008-09-25 Bayer Healthcare Llc Method of analyzing an analyte
CN101652377A (zh) 2007-04-02 2010-02-17 泰拉科斯有限公司 苄基化糖苷衍生物及其用法
JP4809931B2 (ja) 2007-08-23 2011-11-09 セラコス・インコーポレイテッド ベンジルベンゼン誘導体およびその使用方法
BRPI0916769A2 (pt) 2008-07-15 2017-09-26 Theracos Inc derivados de benzilbenzeno deuterados e métodos de uso
PL2324002T3 (pl) 2008-08-22 2017-03-31 Theracos Sub, Llc Sposoby otrzymywania inhibitorów sglt2
ES2554375T3 (es) 2008-11-25 2015-12-18 University Of Rochester Inhibidores de las MLK y métodos de uso
WO2010150100A1 (en) 2009-06-24 2010-12-29 Entarco Sa The use of spinosyns and spinosyn compositions against diseases caused by protozoans, viral infections and cancer
DK2557924T3 (da) 2010-04-13 2019-09-23 Relmada Therapeutics Inc Dermale farmaceutiske sammensætninger af 1-methyl-2',6'-pipecoloxylidid og fremgangsmåde til deres anvendelse
EP2576549A4 (en) 2010-05-24 2013-12-18 Univ Rochester Bicyclic Heteroarylkinase Inhibitors and Methods of Use
WO2011153712A1 (en) 2010-06-12 2011-12-15 Theracos, Inc. Crystalline form of benzylbenzene sglt2 inhibitor
EP2654757A1 (en) 2010-12-22 2013-10-30 Entarco SA The use of spinosyns and spinosyn compositions as local anesthetics and as antiarrhythmic agents
EP3502236B1 (en) 2011-02-18 2023-08-23 The Scripps Research Institute Directed differentiation of oligodendrocyte precursor cells to a myelinating cell fate
US10485800B2 (en) 2012-11-30 2019-11-26 The University Of Rochester Mixed lineage kinase inhibitors for HIV/AIDS therapies
US9420820B2 (en) 2013-08-09 2016-08-23 University Of Tsukuba Method for isolating polyphenols from olive mill water
EP3119394B1 (en) 2014-03-19 2021-05-12 Curza Global LLC Compositions and methods comprising 2-(acylamino)imidazoles
JP2020512981A (ja) 2017-03-31 2020-04-30 カーザ グローバル，リミティド ライアビリティ カンパニー 置換２−アミノイミダゾールを含む組成物と方法
KR20210057053A (ko) 2018-08-23 2021-05-20 씨젠 인크. 항-tigit 항체
MX2023004941A (es) 2020-11-08 2023-07-12 Seagen Inc Conjugado de anticuerpo y fármaco para terapia de combinación con inhibidor de células inmunitarias.
BR112023020662A2 (pt) 2021-04-09 2024-02-06 Seagen Inc Métodos de tratamento de câncer com anticorpos anti-tigit

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3634016A1 (de) * 1986-04-17 1987-10-29 Lohmann Gmbh & Co Kg Flaechenfoermiges therapeutisches system, verfahren zu seiner herstellung und seine verwendung
US5211947A (en) * 1988-12-16 1993-05-18 Schering Corporation Method for lowering blood cholesterol levels with granulocyte-macrophage colony stimulating factor
US5316765A (en) * 1989-09-07 1994-05-31 Karl Folkers Foundation For Biomedical And Clinical Research Use of coenzyme Q10 in combination with HMG-CoA reductase inhibitor therapies
EP0480054B1 (en) * 1990-03-30 1996-10-02 Morimoto, Yasunori Percutaneously absorbable composition of morphine hydrochloride
IL109037A (en) * 1993-03-19 1999-01-26 Cellegy Pharma Inc Preparations for causing phase separation of lipid layers and preparation of the above preparations
DE4341444C2 (de) * 1993-12-04 1996-03-14 Lohmann Therapie Syst Lts Wirkstoffhaltiges Pflaster und Verfahren zu seiner Herstellung
US5968983A (en) * 1994-10-05 1999-10-19 Nitrosystems, Inc Method and formulation for treating vascular disease

Also Published As

Publication number Publication date
PL326497A1 (en) 1998-09-28
AU716896B2 (en) 2000-03-09
ATE186209T1 (de) 1999-11-15
CZ289143B6 (cs) 2001-11-14
US6379696B1 (en) 2002-04-30
PT859595E (pt) 2000-04-28
NO982006D0 (no) 1998-05-04
EP0859595A1 (de) 1998-08-26
AU7085996A (en) 1997-05-29
SK55898A3 (en) 1998-11-04
KR19990067320A (ko) 1999-08-16
EP0859595B1 (de) 1999-11-03
ZA969271B (en) 1997-06-03
NZ318783A (en) 1999-04-29
MY132407A (en) 2007-10-31
CZ136698A3 (cs) 1998-07-15
DE59603597D1 (de) 1999-12-09
CN1201385A (zh) 1998-12-09
NO982006L (no) 1998-05-04
WO1997017061A1 (de) 1997-05-15
JP2001507331A (ja) 2001-06-05
ES2141534T3 (es) 2000-03-16
IL124279A (en) 2003-07-06
GR3032523T3 (en) 2000-05-31
DE19541260A1 (de) 1997-05-07
SK281405B6 (sk) 2001-03-12
KR100445940B1 (ko) 2005-09-30

Similar Documents

Publication Publication Date Title
MX9803563A (es) Preparacion terapeutica para la administracion transdermica de principios activos.
ATE321529T1 (de) Dosierungsform für eine verzögerte und zunehmende wirkstoffsfreisetzung
HK1024865A1 (en) Pharmaceutical compositions comprising a mixture of autocross-linked hyaluronic acid and nonautocross-linked hyaluronic acid and their use for the treatment of arthropathies
NO980700D0 (no) Perifert aktive anti-hyperalgesi opiater
EP0209689A3 (en) Use of tetrahydrobiopterins in the treatment of infantile autism
NZ333724A (en) Enhancing lean tissue mass and bone mineral content by the administration of calcium compositions
ATE186213T1 (de) Transdermale therapeutische systeme enthaltend sexualsteroide
HK1023517A1 (en) Formulation of 5-ht agonists.
UA37259C2 (uk) Активна речовина для одержання лікарських засобів при лікуванні дисфункціональних маткових кровотеч
ES2166783T3 (es) Factor viii activado utilizado como agente terapeutico y metodo para el tratamiento de la deficiencia de factor viii.
DE69613840T2 (de) Orale dosierungsform und verfahren zur behandlung von schmerzzuständen in dermundhöhle
UA70919C2 (uk) Композиція для лікування та запобігання артеріальному тромбозу з використанням інгібітора фактора ха окремо або в комбінації з препаратом, що унеможливлює агрегацію тромбоцитів
IL187254A (en) ANTISENSE NUCLEOTIDES, COMPOSITIONS COMPRISING THEREOF AND THEIR USE IN MODULATING ACTIVATION OF NF-kB
PL335979A1 (en) Antitussive compositions
EP0663835A1 (en) USE OF PARATHORMONE, ITS BIOLOGICALLY ACTIVE FRAGMENTS AND RELATED PEPTIDES FOR THE TREATMENT OF PREGNANCY PROBLEMS.
CA2156481A1 (en) 5-ht2 receptor antagonist compositions useful in treating venous conditions
DE69711078T2 (de) Topische verwendung von kappa-opioidrezeptoragonisten zur behandlung von augenschmerz
PL319259A1 (en) Scopolamine containing plaster
IL140716A0 (en) Use of inhibitors of protein kinase c epsilon to treat pain
MY118986A (en) Use of (alpha)-1-adrenoreceptor antagonists in the prevention and treatment of benign prostatic hyperplasia
ES2002083A6 (es) Un metodo para preparar derivados de piroglutamida
ATE193651T1 (de) Therapeutisches system zur behandlung der psoriasis
IL137489A0 (en) Pharmaceutical compositions containing inhibitors of the lymphotoxin pathway
DE69824853D1 (de) Zusammensetzungen und gegenstände zur verminderung der auswirkung von entzündungen
MY126321A (en) Use of (alpha)-adrenoreceptor antagonists in the prevention and treatment of cancer.

Legal Events

Date Code Title Description
FG Grant or registration
MM Annulment or lapse due to non-payment of fees